Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
2023; American Medical Association; Volume: 10; Issue: 2 Linguagem: Inglês
10.1001/jamaoncol.2023.5410
ISSN2374-2445
AutoresKrishnansu S. Tewari, Nicoletta Colombo, Bradley J. Monk, Coraline Dubot, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, Alexander Arkhipov, Cumhur Tekin, Kan Li, Sarper Toker, Stephen J. O’Keefe, Domenica Lorusso,
Tópico(s)Cervical Cancer and HPV Research
ResumoThe KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. Treatment effects in patient subgroups of the study population are unknown.
Referência(s)